Engene Holdings (ENGNW) | Financial Analysis & Statements
Engene Holdings Inc. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Oct 2025Income Metrics
Revenue
0
Operating Income
-39.5M
Net Income
-37.9M
Balance Sheet Metrics
Total Assets
221.5M
Total Liabilities
53.8M
Shareholders Equity
167.7M
Debt to Equity
0.32
Cash Flow Metrics
Operating Cash Flow
-30.7M
Free Cash Flow
-25.4M
Revenue & Profitability Trend
Engene Holdings Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 94.5M | 38.3M | 16.5M | 15.5M | 12.5M |
| Selling, General & Administrative | 28.7M | 22.1M | 8.5M | 3.3M | 3.2M |
| Other Operating Expenses | - | 1.9M | 1.1M | 700.0K | 253.0K |
| Total Operating Expenses | 123.2M | 62.3M | 26.1M | 19.4M | 15.9M |
| Operating Income | -123.2M | -62.3M | -26.1M | -19.4M | -15.9M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 9.4M | 10.4M | 1.1M | 129.0K | 25.0K |
| Interest Expense | 3.0M | 2.8M | 5.0M | 1.4M | 5.0M |
| Other Non-Operating Income | -569.0K | -479.0K | -70.0M | -3.7M | -2.6M |
| Pre-tax Income | -117.3M | -55.2M | -99.9M | -24.4M | -23.4M |
| Income Tax | 0 | -19.0K | 17.0K | 22.0K | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -117.3M | -55.1M | -99.9M | -24.5M | -23.4M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -113.8M | -51.7M | -81.1M | -19.7M | -15.7M |
| EPS (Basic) | - | - | - | - | - |
| EPS (Diluted) | - | - | - | - | - |
| Basic Shares Outstanding | - | - | - | - | - |
| Diluted Shares Outstanding | - | - | - | - | - |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Engene Holdings Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 50.2M | 173.0M | 81.5M | 20.4M | 11.0M |
| Short-term Investments | 143.6M | 65.3M | 0 | - | - |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 6.6M | 8.6M | 1.5M | 739.0K | 797.0K |
| Total Current Assets | 201.4M | 247.4M | 85.4M | 22.6M | 13.5M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 3.1M | 2.2M | 1.8M | 1.5M | 1.5M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.4M | 1.4M | 930.0K | 939.0K | 939.0K |
| Total Non-Current Assets | 20.1M | 63.8M | 1.5M | 1.3M | 1.5M |
| Total Assets | 221.5M | 311.2M | 87.0M | 23.9M | 15.0M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 6.7M | 1.4M | 1.2M | 723.0K | 1.0M |
| Short-term Debt | 10.0M | 1.1M | 562.0K | 1.3M | 1.1M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 577.0K | 225.0K | 113.0K | - | 21.0K |
| Total Current Liabilities | 32.0M | 14.7M | 5.3M | 5.1M | 3.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 21.8M | 23.9M | 9.2M | 30.8M | 3.0M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 21.8M | 23.9M | 9.2M | 42.3M | 12.1M |
| Total Liabilities | 53.8M | 38.6M | 14.5M | 47.4M | 15.4M |
| Equity | |||||
| Common Stock | 513.3M | 509.8M | 259.4M | 16.4M | 16.4M |
| Retained Earnings | -372.0M | -254.7M | -199.6M | -99.7M | -75.2M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 167.7M | 272.6M | 72.5M | -23.5M | -324.0K |
| Key Metrics | |||||
| Total Debt | 31.8M | 25.0M | 9.8M | 32.1M | 4.2M |
| Working Capital | 169.4M | 232.7M | 80.2M | 17.5M | 10.3M |
Balance Sheet Composition
Engene Holdings Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -117.3M | -55.1M | -99.9M | -24.5M | -23.4M |
| Depreciation & Amortization | 509.0K | 323.0K | 175.0K | 238.0K | 272.0K |
| Stock-Based Compensation | 9.6M | 5.3M | 3.4M | 116.0K | 435.0K |
| Working Capital Changes | 4.6M | 2.4M | -634.0K | -54.0K | 405.0K |
| Operating Cash Flow | -101.3M | -46.1M | -95.2M | -23.5M | -17.4M |
| Investing Activities | |||||
| Capital Expenditures | -1.5M | -925.0K | -318.0K | -153.0K | -247.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -160.8M | -125.0M | 0 | - | - |
| Investment Sales | 137.2M | - | - | - | - |
| Investing Cash Flow | -25.1M | -126.0M | -318.0K | -153.0K | -247.0K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 22.5M | 38.0M | 29.4M | 8.0M |
| Debt Repayment | -699.0K | -9.4M | -4.7M | -1.0M | -964.0K |
| Financing Cash Flow | -699.0K | 259.6M | 86.1M | 28.0M | 22.5M |
| Free Cash Flow | -100.7M | -49.2M | -25.1M | -17.7M | -16.2M |
| Net Change in Cash | -127.1M | 87.6M | -9.4M | 4.3M | 4.9M |
Cash Flow Trend
Engene Holdings Key Financial Ratios
Valuation Ratios
Price to Book
0.55
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-46.07%
Return on Assets
-25.63%
Financial Health
Current Ratio
11.75
Debt to Equity
11.89
Beta
-0.05
Per Share Data
Book Value per Share
$4.20
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ENGNW | 0 | - | 0.55 | -46.07% | 0.00% | 11.89 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Adagene | 243.8M | - | 4.95 | -34.39% | -229.56% | 12.07 |
| Orchestra BioMed | 242.9M | - | 4.48 | -109.41% | -157.40% | 25.17 |
| Third Harmonic Bio | 242.8M | 12.46 | 0.89 | -19.94% | 0.00% | 1.10 |
Financial data is updated regularly. All figures are in the company's reporting currency.






